Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 85 3-Year EPS without NRI Growth Rate is -50.00% as of Dec. 2025. GuruFocus rates DIUXF with a GF Score™ of 85/100 and a GF Value™ of $2.71. The stock has 1 warning sign investors should review. Among 506 Healthcare Providers & Services companies, Diaceutics ranks worse than 93.68% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was -50.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Diaceutics was 226.30% per year. The lowest was -94.10% per year. And the median was -50.00% per year.
Diaceutics (OTCPK:DIUXF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Diaceutics 3-Year EPS without NRI Growth Rate Related Terms
DIUXF vs VEEV, BTSG, HQY: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Diaceutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Diaceutics's 3-Year EPS without NRI Growth Rate falls into.
Diaceutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -50.00% mean?
Diaceutics (DIUXF) has a 3-Year EPS without NRI Growth Rate of -50.00% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Diaceutics and its competitors. According to the industry distribution chart, Diaceutics ranks #474 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 93.7%.
Is Diaceutics' 3-Year EPS without NRI Growth Rate too high?
Diaceutics' current 3-Year EPS without NRI Growth Rate is -50.00%. Based on the distribution chart, Diaceutics ranks #474 out of 506 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Diaceutics has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' 3-Year EPS without NRI Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #474 out of 506 companies for 3-Year EPS without NRI Growth Rate. This places Diaceutics in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.05, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current 3-Year EPS without NRI Growth Rate is -50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Diaceutics (DIUXF) has a current 3-Year EPS without NRI Growth Rate of -50.00%. The stock's GF Value™ is $2.71, compared to a current price of $2.00 — trading 26.2% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -50.00%. Diaceutics' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Diaceutics (DIUXF), the current 3-Year EPS without NRI Growth Rate is -50.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 26.2% below its estimated GF Value™ of $2.71.
Key valuation signals for DIUXF:
3-Year EPS without NRI Growth Rate: -50.00%
GF Value™: $2.71 vs. price of $2.00 (26.2% below fair value)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
85GF Score
Get the complete analysis for DIUXF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
